Market Overview

UPDATE: Jefferies Cuts PT to $5, on VIVUS on Qsymia Shortfall, Higher Expenses

Share:
Related VVUS
Earnings Scheduled For March 9, 2016
Vivus And Oreixigen Have Too Many Problems For Investors, RBC's Simeonidis Claims

Jefferies maintained VIVUS (NASDAQ: VVUS) with an Underperform rating and lowered the price target from $6.00 to $5.00.

Jefferies noted, "The company remains bullish on two key factors that will drive Rx acceleration: the expansion of Qsymia distribution from mail order to retail, which could be approved by April and rolled out in 2H13, and additional formulary wins. We remain cautious on the likelihood of seeing sufficient acceleration in Rx trends to justify the current valuation on a DCF basis, especially as the base of expenses to support the launch is higher than we had previously expected."

VIVUS closed at $12.41 on Monday.

Latest Ratings for VVUS

DateFirmActionFromTo
Feb 2016RBC CapitalDowngradesOutperformSector Perform
Nov 2014Bank of AmericaMaintainsUnderperform
May 2014JP MorganMaintainsNeutral

View More Analyst Ratings for VVUS
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (VVUS)

View Comments and Join the Discussion!